New hope for Hard-to-Treat colorectal cancer? drug combo trial launches

NCT ID NCT07644286

Recruiting now Disease control Sponsor: Tao Zhang Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether combining the drug pirfenidone with an immunotherapy (PD-1 inhibitor), and possibly adding focused radiation, can help people with advanced colorectal cancer that hasn't responded to standard treatments. The study will enroll 48 adults aged 18 to 75 with a specific type of colorectal cancer (pMMR/MSS). Researchers will track how long participants live without their cancer growing and monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirfenidone and a PD-1 inhibitor (a type of immunotherapy), with or without focused radiation therapy
What this could lead to: If this works, it could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 48 participants, so results may not apply to everyone. The combination of drugs and radiation may cause side effects, and there is no guarantee it will shrink tumors or extend life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.